차혁진 (서울대학교 약학대학) | 한빛사논문 > 한빛사

한빛사논문

조회901

서울대학교 약학대학

CV File 176 kb

ACS Central Sci., May 11, 2023 | https://doi.org/10.1021/acscentsci.3c00332 In Silico 5′-Modified 7-Deoxy-7-ethynyl-4′-adenosine as a HASPIN Inhibitor and Its Synergistic Anticancer Effect with the PLK1 Inhibitor

Eun-Ji Kwon,^1‡ Karishma K. Mashelkar,^1‡ Juhee Seo¹, Yoon-Ze Shin¹, Kisu Sung¹, Sung Chul Jang², Sang Won Cheon¹, Haeseung Lee³, Hyuk Woo Lee⁴, Gyudong Kim⁵, Byung Woo Han⁶, Sang Kook Lee², Lak Shin Jeong,^4,6* and Hyuk-Jin Cha^6*

¹College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea
²College of Pharmacy and Natural Products Research Institute, Seoul National University, Seoul 08826, Republic of Korea
³College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of Korea
⁴Future Medicine Company, Limited, Seongnam, Gyeonggi-do 13449, Republic of Korea
⁵College of Pharmacy, and Research Institute of Drug Development, Chonnam National University, Gwangju 61469, Republic of Korea
⁶College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea

E.-J.K. and K.K.M.: These authors contributed equally.
Corresponding Authors : Lak Shin Jeong, Hyuk-Jin Cha

Abstract

Despite genetic perturbations resulting in embryo lethality for most mitotic kinases, loss of the histone H3 mitotic kinase HASPIN reveals no adverse effect in mice models, establishing HASPIN as a promising target for anticancer therapy. However, developing a HASPIN inhibitor from conventional pharmacophores poses a technical challenge as this atypical kinase shares slight similarities with eukaryotic protein kinases. Chemically modifying a cytotoxic 4′-thioadenosine analogue through high genotoxicity yielded several novel nongenotoxic kinase inhibitors. In silico apporoaches utilizing transcriptomic and chemical similarities with known compounds and KINOMEscan profiles unveiled the HASPIN inhibitor LJ4827. LJ4827’s specificity and potency as a HASPIN inhibitor were verified through in vitro kinase assay and X-ray crystallography. HASPIN inhibition by LJ4827 reduced histone H3 phosphorylation and impeded Aurora B recruitment in cancer cell centromeres but not in noncancer cells. Through transcriptome analysis of lung cancer patients, PLK1 was determined as a druggable synergistic partner to complement HASPIN inhibition. Chemical or genetic PLK1 perturbation with LJ4827 effectuated pronounced lung cancer cytotoxicity in vitro and in vivo. Therefore, LJ4827 is a novel anticancer therapeutic for selectively impeding cancer mitosis through potent HASPIN inhibition, and simultaneous HASPIN and PLK1 interference is a promising therapeutic strategy for lung cancer.

논문정보

형식Research article
게재일2023년 05월 (BRIC 등록일 2023-05-12)
연구진국내 연구진
분야 의약학 > 약학

댓글 작성 로그인

CV 열람하기

연락처 보기